Attention Deficit/Hyperactivity Disorder

Authors: Brittany Boos, Pharm.D. Candidate 2014, Harrison School of Pharmacy, Auburn University; Stacie Davis, Pharm.D. Candidate 2014, Harrison School of Pharmacy, Auburn University; Jaimie Dunion, Pharm.D. Candidate 2014, Harrison School of Pharmacy, Auburn University; Bernie R. Olin, Pharm D., Associate Clinical Professor and Director Drug Information Center, Harrison School of Pharmacy, Auburn University

Universal Activity #: 0178-0000-13-100-H01-P | 1.25 credit hours (.125 CEUs) | Expires Dec. 31, 2015
QUIZ - ATTENTION DEFICIT/HYPERACTIVITY DISORDER | ACPE#: 0178-0000-13-100-H01-P

1. What percentage of childhood cases of ADHD will continue into adulthood?
   a. 15%
   b. 30%
   c. 40%
   d. 60%

2. Compared to girls in the United States, boys are how many times more likely to develop ADHD?
   a. 2
   b. 3
   c. 4
   d. 5

3. All of the following are environmental risk factors for ADHD except _____?
   a. Physical inactivity
   b. Maternal smoking
   c. Lead exposure
   d. Low socioeconomic class

4. For the diagnosis of ADHD, all the following are true except _____?
   a. Children must have six or more symptoms from the DSM V criteria
   b. Symptoms must be present prior to age seven
   c. Adult must have five or more symptoms from the DSM V criteria
   d. Symptoms must have been present for greater than six months

5. Which one of the following stimulant medications is available in the largest variety of brand names and formulations?
   a. lisdexamfetamine
   b. methylphenidate
   c. dexmethylphenidate
   d. amphetamine salt

6. Which of the following medications are typically administered once a day?
   a. Adderall XR®
   b. Focalin XR®
   c. Vyvanse®
   d. Concerta®
   e. All of the above

7. Methylphenidate and amphetamine salts block the reuptake of which two neurotransmitters?
   a. Serotonin and dopamine
   b. Gabapentin and serotonin
   c. Dopamine and norepinephrine
   d. Norepinephrine and gabapentin

8. Which one of the following stimulant medications is considered a prodrug?
   a. methylphenidate
   b. amphetamine salts
   c. lisdexamfetamine
   d. dextroamphetamine

9. Which of the following are common side effects of stimulants?
   a. Decreased appetite
   b. Headache
   c. Insomnia
   d. Jitteriness
   e. All of the above

10. Which of the following is not an appropriate management strategy of stimulant-induced irritability?
    a. Dose reduction
    b. Assessment of comorbid conditions
    c. Take stimulant on a full stomach
    d. Initiation of an atypical antipsychotic

11. Which statement below regarding schedule II substances is false?
    a. Must have a manually written prescription
    b. May issue up to a 6 month supply at one time
    c. A separate prescription must be written for each new prescription every month
    d. Must have a currently accepted medical use for treatment in the US

12. Which of the following medication classes are used as non-stimulant therapy for children with ADHD?
    a. Antipsychotics
    b. Antidepressants
    c. Alpha-2-Adrenergic Agonists
    d. All the Above

13. Patients on atomoxetine (Strattera®) therapy are at an increased risk of _____?
    a. Hypotension
    b. Weight Gain
    c. Liver Damage
    d. All the Above

14. Which of the following agents is approved by the FDA for adult ADHD?
    a. Catapres®
    b. Strattera®
    c. Wellbutrin®
    d. Zyprexa®

15. Which of the following medications are considered the second-line agents after stimulant therapy for children and adolescents with ADHD?
    a. Abilify® and Strattera®
    b. Intuniv® and Strattera®
    c. Abilify® and Wellbutrin®
    d. Wellbutrin® and Intuniv®

16. Which of the following medications may cause a patient to experience involuntary muscle contractions?
    a. Haldol®
    b. Pamelor®
    c. Tenex®
    d. Tofranil®

17. Which of the following non-stimulant medications inhibit the reuptake of both norepinephrine and dopamine?
    a. Wellbutrin®
    b. Abilify®
    c. Intuniv®
    d. Strattera®

18. Which of the following are common comorbidities of ADHD?
    a. Diabetes, Migraines, Insomnia
    b. Depression, bipolar disorder, substance abuse
    c. Bipolar disorder, schizophrenia, hypertension
    d. Substance abuse, schizophrenia, Glaucoma
Participant Information:

AL License #____________________

Name___________________________________________________

Address__________________________________________________

City______________________________State_____ Zip__________

E-mail___________________________________________________

NABP e-Profile #__________________________________________

MM/DD (month/day of birth)_______________________________

How long did it take you to read the program and complete this test?

__________ hours   __________ minutes

My signature certifies that I have independently taken this CE examination.

____________________________

CE Assessment Answers
Please circle your answers (one answer per question).

1.   A   B   C   D
2.   A   B   C   D
3.   A   B   C   D
4.   A   B   C   D
5.   A   B   C   D
6.   A   B   C   D   E
7.   A   B   C   D
8.   A   B   C   D
9.   A   B   C   D   E
10.  A   B   C   D
11.  A   B   C   D
12.  A   B   C   D
13.  A   B   C   D
14.  A   B   C   D
15.  A   B   C   D
16.  A   B   C   D
17.  A   B   C   D
18.  A   B   C   D

Program Evaluation - Must be completed for credit.
Please rate the following items on a scale from 1 (poor) to 4 (excellent).
1. Overall quality of the article  1 2 3 4
2. Relevance to pharmacy practice  1 2 3 4
3. Value of the content  1 2 3 4

Please answer each question, marking whether you agree or disagree.
4. This course met the learning objectives.   □ Agree   □ Disagree

Impact of the Activity
The information presented (check all that apply):  
5. □ Reinforced my current practice/treatment habits
   □ Will improve my practice/patient outcomes
   □ Provided new ideas or information I expect to use
   □ Adds to my knowledge
6. Will the information presented cause you to make any changes in how you do your job?  □ Yes   □ No
7. How committed are you to making these changes?  
   (Not committed)  1 2 3 4 (Very committed)
8. Do you feel future activities on this subject matter are necessary and/or important?  □ Yes   □ No

Follow-Up
As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?  □ Yes   □ No